Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Procter & Gamble Co (PG) vs Tempus AI (TEM) Price & Performance

Procter & Gamble CoTrade

Price performance (Past 24H)

Key statistics

Procter & Gamble Co vs Tempus AI — how do they compare? Procter & Gamble Co trades at $143.49 (market cap $338.13B), while Tempus AI trades at $61.18 (market cap $11.67B). The key difference: Procter & Gamble Co is far larger — about 29× Tempus AI's market cap, and Procter & Gamble Co pays a 2.99% dividend while Tempus AI pays none. Which is the better fit depends on your goals.

PGTEM
Market Cap
$338.13B$11.67B
Volume
6,423,436
Sector
Consumer StaplesBroad Market / Factor
52-Week High
$167.18$103.25
52-Week Low
$138.10$41.55
Enterprise Value
$363.97B$12.30B
Dividend Yield
2.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Procter & Gamble Co

Procter & Gamble (PG) trades at $145.59, down 0.57% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $1.89. Fundamentals show robust profitability, including a net income margin of 18.44% and ROE of 30.13%, though valuation ratios like P/E of 21.99 and P/S of 4.05 are at premiums to peers. Recent news highlights PG's dividend reliability and supply chain enhancements.

PG offers stability with consistent dividend growth and solid cash flows, but premium valuation and soft demand outlook pose near-term risks. Analyst consensus is bullish with a $161.20 price target, though technical weakness suggests potential consolidation. Key risks include economic sensitivity and competitive pressures, while institutional activity shows mixed positioning.

Tempus AI

Tempus AI (TEM) trades at $64.29, down 0.51% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats despite negative profitability, with a P/S of 7.99 and P/B of 26.23. Recent catalysts include FDA clearance for an AI ECG product and a $9.5 million ARPA-H award for autonomous AI in cardiology (Business Wire, September 9, 2026).

Outlook remains positive given analyst consensus and growth in precision medicine, but risks include sustained losses, high valuation multiples, and cash burn. The consensus price target is $69.11, implying potential upside, though investors must weigh the company's unprofitability against its innovation pipeline and market position.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Procter & Gamble Co

The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.

Read more on PG

About Tempus AI

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Read more on TEM